Metastatic HER2 -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.
Karen M YunLyudmila BazhenovaPublished in: BMJ case reports (2023)
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2 -mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2 -amplified NSCLC. Here, we present the first reported case of metastatic HER2 -amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- small cell lung cancer
- tyrosine kinase
- squamous cell carcinoma
- brain metastases
- endothelial cells
- cell proliferation
- genome wide
- copy number
- gene expression
- induced pluripotent stem cells
- locally advanced
- dna methylation
- mesenchymal stem cells
- liver metastases
- bone marrow
- protein protein
- solid state
- nucleic acid
- radiation therapy